MSR
SGMO

Main Street Research’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Main Street Research’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,000
Closed -$6K – 111
2023
Q3 		$6K Hold
10,000
– – ﹤0.01% 91
2023
Q2 		$13K Buy
+10,000
New +$13.7K ﹤0.01% 93

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Main Street Research's SGMO Position: Q4 2023 in Review

Main Street Research sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2023, closing a stake of 10,000 shares — an estimated $6K sold.

Main Street Research first reported a position in SGMO in Q2 2023 and held it in 2 quarters. The position peaked at $13K in Q2 2023. 130 funds tracked by Wall St. Rank hold SGMO as of Q4 2023.

  • Main Street Research reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2023 after selling out during the quarter.
  • Main Street Research sold 10,000 SANGAMO THERAPEUTICS INC shares in Q4 2023, an estimated $6K.
  • Main Street Research first reported a position in SANGAMO THERAPEUTICS INC in Q2 2023 and held it in 2 quarters.
  • Main Street Research's SANGAMO THERAPEUTICS INC position peaked at $13K in Q2 2023.
  • 130 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2023.

Based on Main Street Research's 13F filing for Q4 2023, filed 30 Jan 2024.